Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- INSM
- Price
- 66.36
- Stock movement down
- -1.66 (-2.44%)
- Company name
- Insmed Inc
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Market cap
- 11.87B
- Ent value
- 12.98B
- Price/Sales
- 34.62
- Price/Book
- 24.56
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- 4.82%
- 1 year return
- 181.19%
- 3 year return
- 48.53%
- 5 year return
- 21.33%
- 10 year return
- 11.21%
Last updated: 2025-05-29
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
DIVIDENDS
INSM does not pay dividends or no data was received
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 34.62 |
| Price to Book | 24.56 |
| EV to Sales | 37.85 |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 178.90M |
| EPS (TTM) | -4.98 |
| FCF per share (TTM) | -3.66 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 342.96M |
| Gross profit (TTM) | 262.40M |
| Operating income (TTM) | -734.31M |
| Net income (TTM) | -864.28M |
| EPS (TTM) | -4.98 |
| EPS (1y forward) | -4.19 |
Margins
Loading...
Margins data
| Gross margin (TTM) | 76.51% |
| Operating margin (TTM) | -214.11% |
| Profit margin (TTM) | -252.01% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 461.45M |
| Net receivables | 42.32M |
| Total current assets | 1.65B |
| Goodwill | 136.11M |
| Intangible assets | 59.91M |
| Property, plant and equipment | 159.19M |
| Total assets | 2.05B |
| Accounts payable | 64.95M |
| Short/Current long term debt | 999.87M |
| Total current liabilities | 259.19M |
| Total liabilities | 1.57B |
| Shareholder's equity | 483.42M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -618.72M |
| Capital expenditures (TTM) | 17.30M |
| Free cash flow (TTM) | -636.03M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | -178.79% |
| Return on Assets | -42.10% |
| Return on Invested Capital | -59.08% |
| Cash Return on Invested Capital | -43.47% |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 68.00 |
| Daily high | 68.27 |
| Daily low | 66.08 |
| Daily Volume | 4.40M |
| All-time high | 195.00 |
| 1y analyst estimate | 89.40 |
| Beta | 1.12 |
| EPS (TTM) | -4.98 |
| Dividend per share | - |
| Ex-div date | - |
| Next earnings date | 31 Jul 2025 |
Downside potential
Loading...
Downside potential data
| INSM | S&P500 | |
| Current price drop from All-time high | -65.97% | -4.11% |
| Highest price drop | -98.65% | -56.47% |
| Date of highest drop | 25 Nov 2011 | 9 Mar 2009 |
| Avg drop from high | -88.41% | -11.06% |
| Avg time to new high | 898 days | 12 days |
| Max time to new high | 6221 days | 1805 days |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
COMPANY DETAILS
Marketcap
11.87B
Marketcap category
Large-cap
Description
Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases in the United States, Europe, Japan, and internationally. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It is also developing Brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1 for the treatment of patients with bronchiectasis and other neutrophil-mediated diseases; and Treprostinil Palmitil Inhalation Powder, an inhaled formulation of a treprostinil prodrug treprostinil palmitil for the treatment of pulmonary hypertension associated with interstitial lung disease and pulmonary arterial hypertension. The company was founded in 1988 and is headquartered in Bridgewater, New Jersey.
Employees
912
Website
Investor relations
-
SEC filings
CEO
William H. Lewis
Country
USA
City
Bridgewater
Stock type
Common stock
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
iO Charts is a Seeking Alpha partnerNext page